Peptide TT-P34 Passes Phase 1 Trial in Early Parkinson's Disease

A first-in-class neuroprotective peptide has cleared its first human test in Parkinson’s disease. Danish developer Teitur Trophics reported on September 10, 2026 that its lead candidate TT-P34 was safe and well tolerated across a randomized, double-blind, placebo-controlled Phase I trial, and that pharmacokinetic data confirmed the peptide reaches the brain and central nervous system. The company plans to start a Phase II trial in Parkinson’s patients in 2027.

What the Phase I Trial Found

The study ran at the Centre for Human Drug Research in Leiden, the Netherlands. It enrolled 55 healthy volunteers — 31 in a single ascending dose phase and 24 in a multiple ascending dose phase — followed by a separate cohort of 12 patients with early-stage Parkinson’s disease.

Once-weekly subcutaneous administration of TT-P34 was safe and well tolerated at every dose tested, with no dose-limiting findings reported. In the patient cohort, the peptide was also well tolerated when given alongside levodopa, the standard-of-care Parkinson’s medication. Pharmacokinetic analysis showed dose-dependent exposure within the brain and central nervous system, which the company says supports a weekly dosing schedule.

The trial also produced early biomarker signals. Over the 50-day study period, the majority of Parkinson’s patients who received TT-P34 showed a coordinated response across multiple lysosomal proteins measured in cerebrospinal fluid — a finding the company reads as evidence that the pathway the drug is designed to target was actually engaged.

“These data show TT-P34 — which is potentially a game-changer not just for Parkinson’s disease but a range of other neurodegenerative diseases as well — has an excellent safety profile and is well-tolerated, enters the brain and CNS as expected, and has excellent pharmacokinetics,” said Andreas Borta, chief medical officer of Teitur Trophics. “The biomarker data, which indicate engagement of the lysosomal pathway, are also highly encouraging.”

How TT-P34 Is Designed to Work

TT-P34 is a cyclic peptide built to act on two cellular systems at once: mitochondria, which supply cells with energy, and lysosomes, which break down and clear damaged material. Both processes are known to degrade in neurodegenerative disease, contributing to the loss of neurons. The company is also positioning the compound for frontotemporal dementia and Huntington’s disease on the strength of the same mechanism.

That mitochondrial angle places TT-P34 in a research lane that has drawn wider interest this year — the same biology that underlies MOTS-c, a mitochondrial-derived peptide studied for metabolic and cellular-stress regulation. Other neuroactive peptides in the space, including Semax and Dihexa, have been examined largely in preclinical or non-U.S. settings.

The Bar for Parkinson’s Disease Modification Is High

No approved therapy has been shown to slow or stop Parkinson’s disease; existing drugs manage symptoms. That gap has made disease modification one of the hardest targets in neurology, and several better-funded programs have already stumbled.

Ambroxol, which targets the lysosomal enzyme GCase, is in a Phase 3 study. Roche’s prasinezumab, an antibody against alpha-synuclein, entered Phase 3 in 2026 despite missing its primary endpoint in a Phase 2b trial in December 2024. In May 2026, Biogen and Denali’s LRRK2 inhibitor BIIB122 failed to slow progression in a Phase 2b study of early-stage Parkinson’s, missing both primary and secondary endpoints, and the companies discontinued development for idiopathic Parkinson’s disease.

Against that backdrop, TT-P34’s Phase I result is a safety and exposure milestone, not proof of benefit. Phase I trials are designed to establish tolerability and how a drug behaves in the body. Whether the peptide changes disease course in patients is the question the 2027 Phase II study is meant to test.

Teitur’s chief executive framed the unmet need in those terms. “Disease-modifying treatments for Parkinson’s, a condition that seriously affects over 10 million people worldwide, are desperately needed as we can still only manage its symptoms,” said Simon Mølgaard, co-founder and CEO.

Why This Is Not the Same as the Peptide Market

The result lands in a market where the word “peptide” carries two very different meanings. TT-P34 advanced through an investigational new drug process, a reviewed protocol, and objective laboratory endpoints. Products sold directly to consumers online — including grey-market vials marketed for wellness, recovery, or cosmetic use — have no comparable requirement for human safety data.

Regulators have been moving against that second category. The FDA has issued warning letters to multiple peptide vendors, which the agency publishes through its public enforcement warning letters database, and academic reviews continue to find thin evidence behind consumer-facing claims, including a UCLA Health review of common wellness peptides published this month. Coverage of the state of human trial data for BPC-157 has pointed to the same conclusion: the compounds with human data behind them look nothing like the ones being sold at scale.

Teitur plans to present the Phase I data at the International Congress of Parkinson’s Disease and Movement Disorders, held October 4–8 in Seoul, South Korea, with a presentation scheduled for October 5. The company is raising a Series B round to fund the Phase II trial. It spun out of Aarhus University in 2020 and raised a €28 million Series A in 2023.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.